I

IBEX

Biotech company: antibodies and gene therapy

Customer Service Healthcare Representative

Full-TimeDeadline 7/20/27
No salary listed
Entry
Washington, DC, USA
In Person

About the job

Requirements
  • Previous customer service experience, preferably in healthcare or insurance.
  • Strong verbal and written communication skills.
  • Independent decision-making and problem-solving skills, with the ability to remain calm under pressure.
  • Ability to handle high call, chat, and email volumes effectively.
  • Proficiency in computer applications, including customer relationship management and customer support platforms.
  • Ability to work flexible shifts, including weekends and holidays.
  • Must be 18 years or older.
  • High school diploma or equivalent.
Responsibilities
  • Provide guidance on provider networks, referrals, and pre-authorizations.
  • Troubleshoot and resolve issues related to billing, payments, and coverage.
  • Ensure compliance with Health Insurance Portability and Accountability Act regulations when handling sensitive member information.
  • Collaborate with internal departments to resolve complex member concerns.
  • Maintain accurate records of customer interactions and resolutions in customer relationship management systems.
  • Meet performance metrics such as response time, resolution rate, and customer satisfaction scores.
  • Stay updated on policies, state regulations, and healthcare industry changes.
  • Assist members with inquiries related to health insurance coverage, claims, benefits, and provider networks via phone, email, and chat.
Desired Qualifications
  • Healthcare or insurance customer service experience.

About the company

Ibex Biosciences focuses on discovering, validating, and producing biotechnology solutions for health and ecological challenges. Its product portfolio includes therapeutic antibodies, gene therapy, and stem cell programs, as well as diagnostic antibodies for Immunohistochemistry (IHC) to improve biopsy accuracy. The company advances its products by conducting exploratory R&D on projects that may not yet be validated in public research, then develops and commercializes these technologies through licensing, partnerships, and direct sales to healthcare and research institutions. A key differentiator is Ibex’s diversified, internally driven pipeline and its mix of therapeutics and diagnostics, alongside active engagement in grant funding and patenting. The company’s goal is to bring proprietary biotech innovations to market to enhance patient outcomes and health-related research, addressing significant cancer-related and other health challenges.

Company Size

1-10

Company Stage

Early VC

Total Funding

$4.2M

Headquarters

North Bethesda, Maryland

Founded

2015

Get referred to IBEX

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Ibex keeps an open 506(c) offering, signaling active capital formation in 2026.
  • The 2022 CD147 patent supports oncology and inflammation licensing conversations.
  • Anti-MIF VHH development continues, with animal-model testing already disclosed.

What critics are saying

  • Ibex has no disclosed commercial products, leaving revenue dependent on financing.
  • The open Regulation D offering implies dilution risk and financing pressure through 2026.
  • Without clinical validation, the company risks becoming a perpetual patent shop.

What makes IBEX unique

  • North Bethesda-based Ibex Biosciences focuses on antibody, gene-therapy, and stem-cell programs.
  • Its 2026 pipeline spans CD147 antibodies, anti-MIF VHHs, and PCBP1 stem-cell methods.
  • Ibex still controls early patentable assets, including 2022 CD147 publication.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company News

Ibex Innovations
Mar 12th, 2025
IBEX Completes £2m Fundraise for Osteoporosis

IBEX has successfully completed a £2 million funding round to advance its mission of using X-ray technology to diagnose osteoporosis early. The company aims to shift from reactive to proactive treatment of this silent disease. With partnerships established with X-ray and mammography OEMs in 2024, IBEX plans to deploy its technology in clinical settings by 2025, demonstrating cost savings for the NHS.

Globes
Feb 8th, 2022
Gauzy acquires Vision Systems

Israeli light control nanotech and smart glass company Gauzy has announced that it has acquired French company Vision Systems, which develops ADAS (Advanced Driver Assistance System) and shading solutions for the aeronautic, land transport, and marine industries.